Grant of Restricted Inventory Models and Warrants to Staff in Genmab

Read Time:4 Minute, 13 Second

Genmab A/S

Firm Announcement

COPENHAGEN, Denmark; January 24, 2023 Genmab A/S (Nasdaq: GMAB) announced at present that the Board determined to grant 5,408 restricted inventory models to staff of the Firm in addition to the Firm’s subsidiaries and 5,138 warrants to staff of the Firm and the Firm’s subsidiaries.  
 
Every restricted inventory unit is awarded cost-free and gives the proprietor with a proper and obligation to obtain one share in Genmab A/S of nominally DKK 1. The honest worth of every restricted inventory unit is the same as the closing market worth on the date of grant of 1 Genmab A/S share, DKK 2,680.  
 
The restricted inventory models will vest on the primary banking day of the month following a interval of three years from the date of grant. Moreover, the restricted inventory models are topic to vesting circumstances set out within the restricted inventory unit program adopted by the board of administrators. Info regarding Genmab’s restricted inventory unit program may be discovered on www.genmab.com underneath Buyers > Governance > Compensation > Restricted inventory models.  
 
The train worth for every warrant is DKK 2,680. Every warrant is awarded cost-free and entitles the proprietor to subscribe one share of nominally DKK 1 topic to fee of the train worth. By utility of the Black-Scholes formulation, the honest worth of every warrant may be calculated as DKK 939.21.  
 
The warrants vest three years after the grant date, and all warrants expire on the seventh anniversary of the grant date. The brand new warrants have been granted on the phrases and circumstances set out within the warrant program adopted by the board of administrators on February 23, 2021. Info regarding Genmab’s warrant schemes may be discovered on www.genmab.com underneath Buyers > Governance > Compensation > Warrants.

About Genmab
Genmab is a global biotechnology firm with a core objective guiding its unstoppable crew to try in direction of enhancing the lives of sufferers by way of progressive and differentiated antibody therapeutics. For greater than 20 years, its passionate, progressive and collaborative crew has invented next-generation antibody know-how platforms and leveraged translational analysis and knowledge sciences, which has resulted in a proprietary pipeline together with bispecific T-cell engagers, next-generation immune checkpoint modulators, effector operate enhanced antibodies and antibody-drug conjugates. To assist develop and ship novel antibody therapies to sufferers, Genmab has fashioned 20+ strategic partnerships with biotechnology and pharmaceutical firms. By 2030, Genmab’s imaginative and prescient is to remodel the lives of individuals with most cancers and different critical illnesses with Knock-Your-Socks-Off (KYSO) antibody medicines.

Established in 1999, Genmab is headquartered in Copenhagen, Denmark with places in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For extra data, please go to Genmab.com and observe us on Twitter.com/Genmab.

Contact:        
Marisol Peron, Senior Vice President, World Communications & Company Affairs
T: +1 609 524 0065; E: [email protected]

Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: [email protected]

This Firm Announcement accommodates ahead trying statements. The phrases “consider”, “anticipate”, “anticipate”, “intend” and “plan” and comparable expressions determine ahead trying statements. Precise outcomes or efficiency might differ materially from any future outcomes or efficiency expressed or implied by such statements. The vital components that might trigger our precise outcomes or efficiency to vary materially embrace, amongst others, dangers related to pre-clinical and scientific growth of merchandise, uncertainties associated to the result and conduct of scientific trials together with unexpected issues of safety, uncertainties associated to product manufacturing, the dearth of market acceptance of our merchandise, our incapacity to handle development, the aggressive atmosphere in relation to our enterprise space and markets, our incapacity to draw and retain suitably certified personnel, the unenforceability or lack of safety of our patents and proprietary rights, {our relationships} with affiliated entities, adjustments and developments in know-how which can render our merchandise or applied sciences out of date, and different components. For an additional dialogue of those dangers, please consult with the chance administration sections in Genmab’s most up-to-date monetary experiences, which can be found on www.genmab.com and the chance components included in Genmab’s most up-to-date Annual Report on Type 20-F and different filings with the U.S. Securities and Trade Fee (SEC), which can be found at www.sec.gov. Genmab doesn’t undertake any obligation to replace or revise ahead trying statements on this Firm Announcement nor to verify such statements to mirror subsequent occasions or circumstances after the date made or in relation to precise outcomes, except required by regulation.

Genmab A/S and/or its subsidiaries personal the next logos: Genmab®; the Y-shaped Genmab brand®; Genmab together with the Y-shaped Genmab brand®; HuMax®; DuoBody®; DuoBody together with the DuoBody brand®; HexaBody®; HexaBody together with the HexaBody brand®; DuoHexaBody® and HexElect®.

Firm Announcement no. 04
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122

Genmab A/S
Kalvebod Brygge 43
1560 Copenhagen V
Denmark

Attachment

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %
Previous post O.G. Anunoby reportedly desires commerce out of Toronto
Next post O.G. Anunoby reportedly desires commerce out of Toronto